203 related articles for article (PubMed ID: 36451860)
1. Single-cell atlases link macrophages and CD8
Liang Y; Tan Y; Guan B; Guo B; Xia M; Li J; Shi Y; Yu Z; Zhang Q; Liu D; Yang X; Hao J; Gong Y; Shakeel M; Zhou L; Ci W; Li X
Theranostics; 2022; 12(18):7745-7759. PubMed ID: 36451860
[No Abstract] [Full Text] [Related]
2. Clinical and molecular correlates of response to immune checkpoint blockade in urothelial carcinoma with liver metastasis.
Yoshida T; Ohe C; Ito K; Takada H; Saito R; Kita Y; Sano T; Tsuta K; Kinoshita H; Kitamura H; Nishiyama H; Kobayashi T;
Cancer Immunol Immunother; 2022 Nov; 71(11):2815-2828. PubMed ID: 35445305
[TBL] [Abstract][Full Text] [Related]
3. Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing.
Wang L; Sfakianos JP; Beaumont KG; Akturk G; Horowitz A; Sebra RP; Farkas AM; Gnjatic S; Hake A; Izadmehr S; Wiklund P; Oh WK; Szabo PM; Wind-Rotolo M; Unsal-Kacmaz K; Yao X; Schadt E; Sharma P; Bhardwaj N; Zhu J; Galsky MD
Clin Cancer Res; 2021 Aug; 27(15):4287-4300. PubMed ID: 33837006
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes.
Esagian SM; Khaki AR; Diamantopoulos LN; Carril-Ajuria L; Castellano D; De Kouchkovsky I; Park JJ; Alva A; Bilen MA; Stewart TF; McKay RR; Santos VS; Agarwal N; Jain J; Zakharia Y; Morales-Barrera R; Devitt ME; Nelson A; Hoimes CJ; Shreck E; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Rodriguez-Vida A; Drakaki A; Liu S; Kumar V; Lythgoe MP; Pinato DJ; Murgic J; Fröbe A; Joshi M; Isaacsson Velho P; Hahn N; Alonso Buznego L; Duran I; Moses M; Barata P; Galsky MD; Sonpavde G; Yu EY; Msaouel P; Koshkin VS; Grivas P
BJU Int; 2021 Aug; 128(2):196-205. PubMed ID: 33556233
[TBL] [Abstract][Full Text] [Related]
5. Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer.
Rijnders M; Nakauma-González JA; Robbrecht DGJ; Gil-Jimenez A; Balcioglu HE; Oostvogels AAM; Aarts MJB; Boormans JL; Hamberg P; van der Heijden MS; Szabados BE; van Leenders GJLH; Mehra N; Voortman J; Westgeest HM; de Wit R; van der Veldt AAM; Debets R; Lolkema MP
Nat Commun; 2024 Feb; 15(1):1349. PubMed ID: 38355607
[TBL] [Abstract][Full Text] [Related]
6. Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma.
Podojil JR; Glaser AP; Baker D; Courtois ET; Fantini D; Yu Y; Eaton V; Sivajothi S; Chiang M; Das A; McLaughlin KA; Robson P; Miller SD; Meeks JJ
Oncoimmunology; 2020; 9(1):1744897. PubMed ID: 32363111
[TBL] [Abstract][Full Text] [Related]
7. Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors.
Gil-Jimenez A; van Dijk N; Vos JL; Lubeck Y; van Montfoort ML; Peters D; Hooijberg E; Broeks A; Zuur CL; van Rhijn BWG; Vis DJ; van der Heijden MS; Wessels LFA
Nat Commun; 2024 Mar; 15(1):2538. PubMed ID: 38514623
[TBL] [Abstract][Full Text] [Related]
8. Upper Tract Urothelial Carcinoma (UTUC): Prevalence, Impact and Management Challenge.
Nally E; Young M; Chauhan V; Wells C; Szabados B; Powles T; Jackson-Spence F
Cancer Manag Res; 2024; 16():467-475. PubMed ID: 38774494
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of blocking novel immune checkpoint B7-H4 in urothelial carcinoma of bladder as a potential therapeutic target.
Raja D; Singh A; Kurra S; Nayak B; Kaushal S; Sharma A; Singh P
Med Oncol; 2024 Feb; 41(3):74. PubMed ID: 38376603
[TBL] [Abstract][Full Text] [Related]
10. Tumor cell-intrinsic SETD2 inactivation sensitizes cancer cells to immune checkpoint blockade through the NR2F1-STAT1 pathway.
Zheng X; Luo Y; Xiong Y; Liu X; Zeng C; Lu X; Wang X; Cheng Y; Wang S; Lan H; Wang K; Weng Z; Bi W; Gan X; Jia X; Wang L; Wang Y
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056895
[TBL] [Abstract][Full Text] [Related]
11. A deep-learning workflow to predict upper tract urothelial carcinoma protein-based subtypes from H&E slides supporting the prioritization of patients for molecular testing.
Angeloni M; van Doeveren T; Lindner S; Volland P; Schmelmer J; Foersch S; Matek C; Stoehr R; Geppert CI; Heers H; Wach S; Taubert H; Sikic D; Wullich B; van Leenders GJ; Zaburdaev V; Eckstein M; Hartmann A; Boormans JL; Ferrazzi F; Bahlinger V
J Pathol Clin Res; 2024 Mar; 10(2):e12369. PubMed ID: 38504364
[TBL] [Abstract][Full Text] [Related]
12. Transcriptomic Profiling of Upper Tract Urothelial Carcinoma: Bladder Cancer Consensus Classification Relevance, Molecular Heterogeneity, and Differential Immune Signatures.
Fontugne J; Xylinas E; Krucker C; Dixon V; Groeneveld CS; Pinar U; Califano G; Bucau M; Verine J; Desgrandchamps F; Hermieu JF; Radvanyi F; Allory Y; Masson-Lecomte A
Mod Pathol; 2023 Nov; 36(11):100300. PubMed ID: 37558130
[TBL] [Abstract][Full Text] [Related]
13. Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8
Yu A; Hu J; Fu L; Huang G; Deng D; Zhang M; Wang Y; Shu G; Jing L; Li H; Chen X; Yang T; Wei J; Chen Z; Zu X; Luo J
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37802603
[TBL] [Abstract][Full Text] [Related]
14. [Profile and immune environment of upper tract urothelial carcinoma].
Gallon J; LeMaoult J; Verine J; Dumont C; Djouadou M; Carosella E; Rouass-Freiss N; Desgrandchamps F; Masson-Lecomte A
Prog Urol; 2023 Dec; 33(15-16):983-992. PubMed ID: 37872060
[TBL] [Abstract][Full Text] [Related]
15. Current trends in the promising immune checkpoint inhibition and radiotherapy combination for locally advanced and metastatic urothelial carcinoma.
Sano T; Saito R; Aizawa R; Watanabe T; Murakami K; Kita Y; Masui K; Goto T; Mizowaki T; Kobayashi T
Int J Clin Oncol; 2023 Dec; 28(12):1573-1584. PubMed ID: 37874429
[TBL] [Abstract][Full Text] [Related]
16. The tumour-associated stroma correlates with poor clinical outcomes and immunoevasive contexture in patients with upper tract urothelial carcinoma: results from a multicenter real-world study (TSU-01 Study).
Xu L; Zhong W; Li C; Hong P; Xia K; Lin R; Cheng S; Wang B; Yang M; Chen J; Ma L; Li X; Zhou L; Huang J; Lin T
Br J Cancer; 2023 Jan; 128(2):310-320. PubMed ID: 36396819
[TBL] [Abstract][Full Text] [Related]
17. ADGRE5-centered Tsurv model in T cells recognizes responders to neoadjuvant cancer immunotherapy.
Li J; Meng Z; Cao Z; Lu W; Yang Y; Li Z; Lu S
Front Immunol; 2024; 15():1304183. PubMed ID: 38343549
[TBL] [Abstract][Full Text] [Related]
18. The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer.
Boll LM; Perera-Bel J; Rodriguez-Vida A; Arpí O; Rovira A; Juanpere N; Vázquez Montes de Oca S; Hernández-Llodrà S; Lloreta J; Albà MM; Bellmunt J
Sci Rep; 2023 Sep; 13(1):15287. PubMed ID: 37714872
[TBL] [Abstract][Full Text] [Related]
19. The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysis.
Ohara K; Rendeiro AF; Bhinder B; Eng KW; Ravichandran H; Nguyen D; Pisapia D; Vosoughi A; Fernandez E; Shohdy KS; Manohar J; Beg S; Wilkes D; Robinson BD; Khani F; Bareja R; Tagawa ST; Ouseph MM; Sboner A; Elemento O; Faltas BM; Mosquera JM
Nat Commun; 2024 Mar; 15(1):2009. PubMed ID: 38499531
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast Growth Factor Inhibitors for Treating Locally Advanced/Metastatic Bladder Urothelial Carcinomas via Dual Targeting of Tumor-Specific Oncogenic Signaling and the Tumor Immune Microenvironment.
Lee HW; Seo HK
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
